CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company’s therapeutic development programs, VIMOVO™ (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act. As a result, the Company will receive a non-taxable cash grant totaling approximately $730,000, which will be recorded as income in the 2010 fourth quarter.
